Eli Lilly and Novo Nordisk have had multiple FDA-approved GLP-1 drugs on the market since 2022, though record-high demand, chronic supply shortages and pricing concerns have created challenges for the drugmakers
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV
This is where non-invasive body contouring treatments come in
Uninsured patients pay $900$1,500 monthly for brand-name Wegovy through retail pharmacies
Natalie Hernandez is a pediatric endocrinologist with advanced fellowship training in pediatric obesity medicine, metabolism, diabetes, and hormone health
Immune cell infiltration into the brain after ischemic stroke in humans compared to mice and rats: a systematic review and meta-analysis